Eikon Therapeutics has submitted an Investigational New Drug (IND) application to the FDA for EIK1006, a novel androgen receptor antagonist designed to treat advanced metastatic prostate cancer. Unlike existing treatments, EIK1006 targets both wild-type and resistant variants of the androgen receptor, potentially overcoming therapy resistance. This IND submission marks a key step toward clinical trials, aiming to offer a new option for patients with difficult-to-treat prostate cancer. Eikon leverages advanced imaging technology to develop innovative cancer therapies and plans to evaluate EIK1006's clinical benefits soon.
Eikon Therapeutics' IND submission for its novel prostate cancer drug EIK1006 provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 15, 2026 18:13 WIB: out of 150 priced US health-sector stocks, 93 rose and 49 fell. Notable movers include NVAX at USD 12.24 with a 1-day change of -3.16% and 72% sell order activity, DXCM at USD 86.00 with a 3.03% gain and 100% buy order activity, and CTXR at USD 0.45 with a -3.01% change and 100% buy order activity.
TiDB, powered by PingCAP, announced new cloud platform capabilities to support enterprise and AI applications on a unified data foundation. Key updates include the upcoming general availability of TiDB Cloud Premium, public previews of Bring Your Own...
The Saudi Arabia Non-Invasive Prenatal Testing (NIPT) market is projected to grow from $52.5 million in 2025 to $162.16 million by 2034, at a CAGR of 13.35%. Growth is fueled by rising maternal age, advances in molecular diagnostics, and increased he...
ONEOK completed a $4.425 billion acquisition of Brazos Midstream's natural gas assets, doubling its processing capacity in the Permian Midland Basin to about 2.3 billion cubic feet per day. The deal secures 600,000 acres under long-term contracts, st...
Charles Schwab reported Q3 earnings per share of $1.69, beating estimates despite slightly missing revenue forecasts with $7.17 billion. The quarter marked a 17% revenue increase year-over-year and a 23% rise in net income to $2.91 billion, driven by...
Alcoa will release its Q3 2026 earnings on October 15, with analysts divided on earnings per share and revenue forecasts due to factors like rising aluminum sales, inventory changes, and higher input costs. The company expects a 54.9% jump in aluminu...
